Bladder Cancer

Schmidt notes that differences in response rates between disease subtypes largely reflect inherent tumor biology.

The data, presented at ESMO, support a role for gemcitabine intravesical system plus cetrelimab in MIBC.

The authors suggested that a greater treatment effect may be observed with a more antigenic vaccine.

AVZO-103 is a Nectin-4/TROP2 biospecific antibody-drug conjugate for adult patients with urothelial carcinoma whose tumors have progressed on enfortumab vedotin.

A key finding was that 86% of patients required no additional therapy after receiving nadofaragene.

The approval is supported by results from the phase 3 KEYNOTE-905/EV-303 trial.

Notably, 81% of patients said that they were interested in trying new or different treatment options.

One particularly striking finding from KEYNOTE-905/EV-303 is the nearly 60% pathologic complete response rate.

The CxBladder Triage Plus Test identifies patients with hematuria who are at higher risk for urothelial carcinoma.

Joshua J. Meeks, MD, PhD, highlights that collaboration between urologists and medical oncologists has become essential.

John Eifler, MD, highlights new real-world evidence on nadofaragene firadenovec-vncg for BCG-unresponsive NMIBC.

Suzanne B. Merrill, MD, FACS, discussed the feasibility of integrating immune checkpoint inhibitors into clinical practice for NMIBC, particularly in the community setting.

Safety outcomes were favorable: cystectomy-free survival was 94%, overall survival was 100%, and only 1 patient progressed to muscle-invasive disease.

Mobley also shares her treatment approach to BPH and explains the challenges of treating OAB.

"I'm very excited to bring this therapy to our patients in the Philadelphia area and to be able to offer it at MidLantic," says David Cahn, DO, MBS, FACOS.

"For me and the patients, [nadofaragene firadenovec is] a very convenient dosing schedule, and it's a very efficacious treatment," says Ravi D. Chauhan, MD, FACS.

Looking forward, Meeks said he sees nadofaragene firadenovec as a promising addition to the NMIBC treatment landscape.

Suzanne Merrill, MD, outlines recent progress with immunotherapy across NMIBC and MIBC.

The FDA has confirmed that results from the UTOPIA trial can support submission of an NDA for UGN-103.

The study is assessing FL115 in combination with BCG in patients with non-muscle invasive bladder cancer.

Liu notes that current data—showing a response rate of just over 50%—indicate that the BCG-unresponsive CIS cohort is the most appropriate initial target population.

A recap of the FDA submissions and regulatory decisions in urology from October 2025.

Explore the evolving landscape of non-muscle invasive bladder cancer treatments, focusing on the promising gene therapy detalimogene voraplasmid and its trial results.

Petros Grivas, MD, PhD, touches on the signficance of KEYNOTE-905 data, which were presented at ESMO 2025.